Theriva Biologics
TOVX
53 hedge funds and large institutions have $20.6M invested in Theriva Biologics in 2017 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 14 increasing their positions, 15 reducing their positions, and 27 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% less ownership
Funds ownership: 0% → 0% (-0%)
7% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 15
25% less capital invested
Capital invested by funds: $27.4M → $20.6M (-$6.78M)
28% less funds holding
Funds holding: 74 → 53 (-21)
78% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 27
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$633K |
| 2 |
Millennium Management
New York
|
+$523K |
| 3 |
ECM
Element Capital Management
New York
|
+$274K |
| 4 |
PP
Paloma Partners
Greenwich,
Connecticut
|
+$209K |
| 5 |
LP
LMR Partners
London,
United Kingdom
|
+$194K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$2.52M |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$712K |
| 3 |
State Street
Boston,
Massachusetts
|
-$513K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$478K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$228K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
Wells Fargo
San Francisco,
California
| – | -$19.9K | -4 | Closed |
|
77
Renaissance Technologies
New York
| – | -$14K | -3 | Closed |
|
|
CS
78
Credit Suisse
Zurich,
Switzerland
| – | -$10K | -2 | Closed |
|
79
Principal Financial Group
Des Moines,
Iowa
| – | -$11K | -2 | Closed |
|
80
SG Americas Securities
New York
| – | -$13K | -2 | Closed |
|
|
AB
81
Amalgamated Bank
New York
| – | -$7K | -1 | Closed |
|
|
AIP
82
Ameritas Investment Partners
Lincoln,
Nebraska
| – | -$4K | -1 | Closed |
|
83
Legal & General Group
London,
United Kingdom
| – | -$6K | -1 | Closed |
|
84
ProShare Advisors
Bethesda,
Maryland
| – | -$7K | -1 | Closed |
|
|
AA
85
Apriem Advisors
Irvine,
California
| – | -$1K | – | – |
|
|
OCM
86
Oakview Capital Management
Dallas,
Texas
| – | -$2K | – | – |
|
TOVX Hedge Fund Activity: Q2 2017 in Review
53 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Theriva Biologics (TOVX) for Q2 2017, worth a combined $20.6M — down 25% from $27.4M a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of TOVX and 6 opened new positions — a net loss of 21 holders — while 15 trimmed existing stakes and 14 added.
The largest buyer was Goldman Sachs, adding an estimated $633K. The largest seller was BlackRock, cutting an estimated $2.52M.
- 53 institutional investors held Theriva Biologics (TOVX) as of Q2 2017, down from 74 in Q1 2017.
- Funds reported $20.6M of Theriva Biologics stock for Q2 2017, down 25% quarter-over-quarter.
- 6 funds opened new Theriva Biologics positions in Q2 2017 and 27 closed out, a net change of -21 holders.
- The largest Theriva Biologics buyer in Q2 2017 was Goldman Sachs, an estimated $633K added.
- The largest Theriva Biologics seller in Q2 2017 was BlackRock, an estimated $2.52M sold.
Based on aggregated 13F filings for Q2 2017.